Please assess the completion status of the following clinical trial:

Trial Title: NAC +taVNS in IDM Who Are Poor Oral Feeders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Infants of diabetic mothers who are failing oral feeding, \>39weeks gestation at enrollment, who are clinically stable, on minimal respiratory support (nasal cannula or room air), and clinical team has determined are G-tube candidates~Exclusion Criteria:~* Unstable infants or those requiring positive pressure respiratory support~* Infants \<39 weeks gestation at enrollment~* Major unrepaired congenital anomalies or anomalies that limit feeding volumes~* Infants with cardiomyopathy~* Repeated episodes of autonomic instability (apnea/ bradycardia) not self resolving

- Gender: ALL
- Minimum Age: 3 Weeks
- Maximum Age: 5 Months
- Healthy Volunteers: f

Study Arms:
- NAC + taVNS (Type: EXPERIMENTAL): NAC will be given via nasogastric tube (n,g.) 100mg/kg loading dose, then 75mg/kg/dose n.g. q 6h, administered 1h before a feed, for a total of 14 days. taVNS will be administered to left ear during active sucking with 2 daily feedings starting after 4 days of NAC, continuing for 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).